Lung cancer
KRAS inhibition comes of age for lung cancer?
A phase 2 study of sotorasib in advanced KRAS p.G12C mutated non-small cell lung cancer has delivered promising results including a disease control rate of 80.6%.
Dr Bob Li, from the Memorial Sloan Kettering Cancer Centre in the US, presented the...
A phase 2 study of sotorasib in advanced KRAS p.G12C mutated non-small cell lung cancer has delivered promising results including...